{"analyses":[{"ciLowerLimit":"1.0680","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"1.5061","groupIds":["OG000","OG001","OG002"],"nonInferiorityType":"SUPERIORITY_OR_OTHER","pValue":"0.0067","paramType":"Odds Ratio (OR)","paramValue":"1.2683","statisticalMethod":"Chi-squared","testedNonInferiority":false}],"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"357"},{"groupId":"OG001","value":"1375"},{"groupId":"OG002","value":"1441"}]}],"title":"30 MIU/day"},{"categories":[{"measurements":[{"groupId":"OG000","value":"189"},{"groupId":"OG001","value":"1159"},{"groupId":"OG002","value":"1402"}]}],"title":"48 MIU/day"}],"denomUnitsSelected":"Participants","denoms":[{"counts":[{"groupId":"OG000","value":"151"},{"groupId":"OG001","value":"647"},{"groupId":"OG002","value":"631"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"546"},{"groupId":"OG001","value":"2534"},{"groupId":"OG002","value":"2843"}],"units":"cycles"}],"description":"Objective 2: To describe EP2006 primary or secondary prophylaxis patterns for FN over up to 6 cycles of chemotherapy, with or without prior, concurrent, or later radiotherapy or surgery.","groups":[{"description":"Cancer patients with chemotherapy toxicity \\<10% treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG000","title":"EP2006: Risk <10%"},{"description":"Cancer patients with chemotherapy toxicity 10-20% treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG001","title":"EP2006: Risk 10-20%"},{"description":"Cancer patients with chemotherapy toxicity \\>20% treated with chemotherapy and who are prescribed commercially available filgrastim biosimilar for primary or secondary prophylaxis for FN.","id":"OG002","title":"EP2006: Risk >20%"}],"paramType":"NUMBER","reportingStatus":"POSTED","timeFrame":"All cycles. Patients were evaluated at the enrollment cycle and then re-evaluated at each cycle for a maximum total of 6 cycles; however, the scheduling of these evaluations was left to the discretion of the physician, mean duration of study for 105 days","title":"EP2006 Dose by Chemotherapy Toxicity: Cycle Level","type":"PRIMARY","typeUnitsAnalyzed":"cycles","unitOfMeasure":"cycles"}